The Daily Brief The greatest corporate failure in history
Aug 28, 2025
Dive into the dramatic collapse of Evergrande and its ripple effects on China's economy and citizens facing financial turmoil. Explore the rise of Contract Development and Manufacturing Organizations in India, set to revolutionize the pharmaceutical sector. The podcast highlights how evolving opportunities in global biotech could shift power dynamics away from China, while exciting developments in India's economy, such as Tata Motors' restructuring, signal a promising future. It's a captivating journey through corporate upheavals and emerging markets!
AI Snips
Chapters
Transcript
Episode notes
China's Biotech Leapfrogged Early Rivals
- China invested heavily and moved faster to become a biotech powerhouse, running many trials and launching dozens of new medicines yearly.
- That scale makes China a hard competitor for complex biologics and advanced manufacturing.
Diversify Pharma Supply Chains
- Diversify supply chains away from a China-only model to reduce geopolitical and concentration risk.
- Use India's CDMO capacity as a secondary supplier for resilience, especially after Covid exposed vulnerabilities.
The Goldmine Of Long-Term Supply Deals
- CDMOs aim to win long-term, high-margin contracts post-approval because they supply approved drugs for years.
- Securing these contracts creates sticky revenue and substantial lifetime value for manufacturers.